Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CORCEPT THERAPEUTICS INC Director's Dealing 2016

Nov 15, 2016

30681_dirs_2016-11-14_0bb52e01-77ce-4871-8af2-39495a3d3e32.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2016-11-10

Reporting Person: BELANOFF JOSEPH K (Director, CHIEF EXECUTIVE OFFICER)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-11-10 Common Stock M 300000 $1.50 Acquired 2464195 Direct
2016-11-10 Common Stock S 300000 $8.9015 Disposed 2164195 Direct
2016-11-11 Common Stock M 200000 $1.50 Acquired 2364195 Direct
2016-11-11 Common Stock S 200000 $9.1015 Disposed 2164195 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-11-10 Stock Option (Right to Buy) $1.50 M 300000 Disposed 2017-04-16 Common Stock (300000) Direct
2016-11-11 Stock Option (Right to Buy) $1.50 M 200000 Disposed 2017-04-16 Common Stock (200000) Direct

Footnotes

F1: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.86 to $9.039 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.

F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.91 to $9.36 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request.

F3: Fully exercisable.